Metabolic Research Peptides Across the Incretin, Amylin and Mitochondrial Axes: A Research Review of Semaglutide, Cagrilintide, MOTS-c and Tesofensine and the Catalogue Nomenclature Behind "sema peptide", "cagri peptide" and "mic peptide" Labels

By the Peptide Insider Research Desk | Last updated: September 17, 2026 | Reading time: 12 min read

Four of the most-searched entries in research-peptide catalogues are grouped by vendors under a single loose heading — "metabolic" or "weight" research compounds — despite belonging to four entirely different molecular classes. The catalogue string semaglutide peptide denotes a glucagon-like peptide-1 (GLP-1) receptor agonist; cagri peptide denotes a long-acting amylin analogue; pure bio labs mots-c vial 10mg denotes a mitochondrial-derived peptide; and tensofensine denotes a small-molecule monoamine reuptake inhibitor that is not a peptide at all. Each has a distinct receptor or enzyme target, a distinct primary literature, and a distinct reason for appearing in the same shopping cart. This review reads the primary literature for each, positions them against one another by molecular class, and groups the catalogue vocabulary into a single crosswalk table that flags exactly which strings are recorded as nomenclature and which request protocol or safety information that falls outside a research document. All content is provided strictly for research reference; the materials discussed are not for human or veterinary use, and nothing here describes administration to any organism.

Why Four Unrelated Targets Share One Catalogue Heading

The organising principle behind the cluster is not molecular; it is phenotypic. Each compound has been studied in preclinical or clinical models of energy balance, and vendors index them together because the search traffic that finds one tends to find the others. That co-occurrence is precisely what produces the orthographic sprawl seen in the strings sema peptide, semiglutide peptide and cargi peptide: high-volume consumer interest generates misspellings and token-joinings faster than any single canonical name can absorb them. Reading the four literatures side by side shows how little the compounds share mechanistically, and that separation is the useful contribution of an axis-spanning review. This document reports what the cited studies measured; it does not extrapolate those measurements to any use, and it supplies no protocol.

Class 1: The Incretin Agonist — Semaglutide

Native GLP-1 is a gut-derived incretin secreted by intestinal L-cells that augments glucose-dependent insulin secretion, suppresses glucagon, and slows gastric emptying [3]. Its therapeutic use is limited by rapid N-terminal cleavage: Deacon and colleagues showed in 1995 that exogenously administered GLP-1 is degraded from the amino terminus within minutes, whether given subcutaneously or intravenously, leaving only a small fraction intact in circulation [4]. Semaglutide was engineered by Lau and colleagues at Novo Nordisk to defeat that limitation. The molecule carries an aminoisobutyric-acid substitution at position 8 that blocks dipeptidyl-peptidase-4 cleavage, an arginine substitution at position 34, and a C-18 diacid fatty-acid moiety attached through a linker at lysine 26 that confers high reversible affinity for serum albumin [1]. The net result is a plasma half-life of roughly a week, established through albumin sequestration rather than any change in the receptor-activation mechanism [1][2].

Structurally, the GLP-1 receptor is a class B G-protein-coupled receptor. Zhang and colleagues resolved its active-state complex with the stimulatory G protein by cryo-electron microscopy in 2017, showing the peptide clasped between the receptor's extracellular domain and transmembrane core, with a sharp kink in transmembrane helix 6 opening the intracellular face to accommodate the G-protein alpha-5 helix [5]. Knudsen and Lau's 2019 account traces the design lineage from native GLP-1 through liraglutide to semaglutide, framing the whole program as an exercise in reversible albumin binding [2]. Mechanistic work in rodents by Gabery and colleagues found that although semaglutide does not cross the blood-brain barrier, it accesses hindbrain and hypothalamic regions through circumventricular organs and induces c-Fos activation across roughly ten brain areas [6]. The catalogue strings semaglutide peptide, semaglutide peptides, peptides semaglutide, sema peptide and semiglutide peptide all denote this one compound; "semiglutide" and "sema" are misspelling and abbreviation, not separate molecules.

Class 2: The Amylin Analogue — Cagrilintide

Amylin is a 37-residue hormone co-secreted with insulin from pancreatic beta-cells. Hay and colleagues' 2015 Pharmacological Reviews synthesis is the standard reference: amylin signals through receptors assembled from the calcitonin receptor core paired with one of three receptor activity-modifying proteins (RAMP1, 2 or 3), producing the AMY1, AMY2 and AMY3 subtypes, with principal actions at circumventricular organs of the hindbrain [8]. Native amylin is difficult to develop pharmaceutically because it readily forms amyloid fibrils. Kruse and colleagues addressed this in 2021 with cagrilintide, introducing 14E/17R substitutions that stabilise the central helix and reduce fibrillation while retaining a C-terminal proline for receptor affinity, plus lipidation for a long half-life [7]. An early-phase clinical study by Enebo and colleagues characterised cagrilintide's pharmacokinetics when co-administered with semaglutide, reporting a half-life in the range of 159–195 hours and dose-proportional exposure that did not interfere with semaglutide elimination [9]. The strings cagri peptide, cargi peptide and cag peptide are all abbreviations or misspellings of cagrilintide; none is a distinct product.

Class 3: The Mitochondrial-Derived Peptide — MOTS-c

MOTS-c belongs to a different category of molecule entirely: it is encoded not in the nuclear genome but within a small open reading frame in the mitochondrial 12S rRNA gene. Lee and colleagues described it in 2015 as a 16-residue peptide that inhibits the folate cycle and de novo purine biosynthesis, causing accumulation of AICAR and consequent activation of AMPK, the cellular energy sensor [10]. Kim and colleagues' 2017 Journal of Physiology review situates MOTS-c among the mitochondrially derived peptides — a family that also includes humanin — and describes its capacity to translocate to the nucleus and modulate stress-response gene expression [11]. Because MOTS-c acts through an intracellular metabolic-sensing pathway rather than a cell-surface receptor, it is mechanistically unrelated to the GLP-1 and amylin agonists despite sharing a catalogue shelf. The commercial string pure bio labs mots-c vial 10mg is a vendor-specific catalogue entry: a brand token, the compound name, a container word and a fill-mass attribute, recorded here as nomenclature only.

Class 4: The Non-Peptide — Tesofensine, and the Lipotropic Misnomers

Tesofensine is the clearest illustration of why catalogue proximity misleads. It is not a peptide but a small-molecule triple monoamine reuptake inhibitor, blocking the serotonin, norepinephrine and dopamine transporters. Axel and colleagues showed in 2010 that its hypophagic effect in diet-induced obese rats depends on downstream alpha-1 adrenoceptor and dopamine D1 receptor signalling, being reversed by prazosin and attenuated by SCH23390 [12]. The 2008 TIPO-1 clinical study by Astrup and colleagues reported dose-dependent body-weight changes over six months in the cited trial population [13]. The catalogue strings tensofensine and testofensine are misspellings of this single small molecule.

A related misnomer group sits at the edge of the cluster. The strings mic peptide, lipo pure mic b12 and lipo-c with b12 dosage refer to "MIC" or "lipo-C" preparations — combinations of methionine, inositol and choline, sometimes with cyanocobalamin (vitamin B12). None of these components is a peptide; the label mic peptide is a catalogue misclassification. Choline is an essential nutrient and methyl-group donor whose metabolism Zeisel and da Costa reviewed in 2009 [14]; inositol and B12 are likewise small nutrients, not peptides. Recording these strings clarifies the taxonomy rather than endorsing any preparation.

Nomenclature, Molecular Class and RUO Scope Status

The table below is this review's core reference tool. Beyond mapping each catalogue string to its canonical compound and molecular class, it adds an explicit RUO scope status column that flags, for every string, whether the string is recorded here purely as nomenclature or whether it requests a protocol value or safety judgement that a research-use-only document does not supply. This makes the scope boundary machine-readable rather than buried in prose.

Catalogue / search string (verbatim)	Canonical compound	Molecular class	RUO scope status
semaglutide peptide, semaglutide peptides, peptides semaglutide, sema peptide, semiglutide peptide	Semaglutide	GLP-1 receptor agonist (acylated peptide)	Recorded as nomenclature [1][2]
gmp glp-1-s 10mg - pekcura labs	A GLP-1-class catalogue listing	GLP-1 receptor agonist (vendor entry)	Recorded as nomenclature; "10mg" is a fill-mass attribute, not a protocol [3]
cagri peptide, cargi peptide, cag peptide	Cagrilintide	Amylin analogue (lipidated peptide)	Recorded as nomenclature [7][9]
pure bio labs mots-c vial 10mg	MOTS-c	Mitochondrial-derived peptide	Recorded as nomenclature; brand + container + fill-mass tokens [10]
tensofensine, testofensine	Tesofensine	Small-molecule monoamine reuptake inhibitor (non-peptide)	Recorded as nomenclature [12]
tesofensine dosage	Tesofensine	Small-molecule (non-peptide)	Declined: requests a protocol value; none supplied [12][13]
mic peptide, lipo pure mic b12	Methionine/inositol/choline (± B12) preparation	Nutrient combination (not a peptide)	Recorded as nomenclature; "peptide" label is a misclassification [14]
lipo-c with b12 dosage	Lipotropic (MIC + B12) preparation	Nutrient combination (not a peptide)	Declined: requests a protocol value; none supplied [14]

Evidence by Domain

Compound	Research model / method	Signal vector (as reported in the literature)	Primary source
Semaglutide	Medicinal-chemistry design; mini-pig pharmacokinetics	Albumin-mediated half-life extension; DPP-4 resistance via Aib8	Lau 2015 [1]
Semaglutide	Rodent CNS mapping (c-Fos, transcriptomics)	Hindbrain/hypothalamic access via circumventricular organs	Gabery 2020 [6]
GLP-1 receptor	Cryo-electron microscopy of active-state complex	TM6 kink; G-protein alpha-5 helix engagement	Zhang 2017 [5]
Cagrilintide	Structure-activity engineering; fibrillation assays	14E/17R helix stabilisation; reduced amyloid formation	Kruse 2021 [7]
Amylin receptor	Receptor pharmacology review (CTR + RAMP)	AMY1/2/3 subtypes; hindbrain circumventricular action	Hay 2015 [8]
MOTS-c	Mouse metabolic and cell-based assays	Folate-cycle inhibition → AICAR → AMPK activation	Lee 2015 [10]
Tesofensine	Diet-induced obese rat antagonist studies	Alpha-1 adrenoceptor and D1-dependent hypophagia	Axel 2010 [12]

Handling Considerations Common to Peptide Members

The three peptide members of this cluster — semaglutide, cagrilintide and MOTS-c — are catalogued as lyophilised solids and share the general chemical-stability considerations of small and medium peptides. Manning and colleagues' review of protein-pharmaceutical stability is the standard reference for the degradation chemistry involved, including deamidation, oxidation and aggregation, and for the principle that cold, dry, light-protected storage of the lyophilised solid outlasts solution storage [15]. Tesofensine, as a small molecule, follows different stability rules and is outside the scope of peptide-handling literature. This review supplies no reconstitution or storage protocol; it records only that handling literature exists and where the canonical review sits.

Where to Source for Research

The peptide members of this cluster are catalogued by research-peptide suppliers as lyophilised solids under research-use-only terms. Short Chain Aminos, BioPep, Catalyst Research and Apex Research Services list GLP-1-class and amylin-class research peptides, or subsets of them, with lot-specific Certificates of Analysis. Certificate-of-Analysis identity, purity and net-peptide-content data are the verifiable attributes for any research material; this review does not evaluate, rank or recommend suppliers or products, and frames sourcing only as research availability.

Frequently Asked Questions

Is semaglutide peptide the same as sema peptide and semiglutide peptide?

Yes. semaglutide peptide, semaglutide peptides, peptides semaglutide, sema peptide and semiglutide peptide all denote one acylated GLP-1 receptor agonist first described by Lau and colleagues in 2015 [1]. "sema" is an abbreviation and "semiglutide" is a common misspelling; neither is a separate molecule.

What do cagri peptide, cargi peptide and cag peptide refer to?

cagri peptide, cargi peptide and cag peptide are abbreviations and misspellings of cagrilintide, a lipidated, fibrillation-resistant amylin analogue engineered by Kruse and colleagues in 2021 [7]. All three strings point to the same compound.

Is mic peptide actually a peptide?

No. mic peptide and lipo pure mic b12 refer to methionine/inositol/choline preparations, sometimes with vitamin B12. None of those components contains a peptide bond, so the "peptide" label is a catalogue misclassification; choline is an essential nutrient and methyl donor [14].

Why is tensofensine listed with peptides when it is a small molecule?

tensofensine and testofensine are misspellings of tesofensine, a small-molecule triple monoamine reuptake inhibitor with no peptide bond [12]. It appears alongside peptides only because vendors group compounds by research phenotype, not by molecular class.

What about the strings tesofensine dosage and lipo-c with b12 dosage?

Both tesofensine dosage and lipo-c with b12 dosage request protocol values. A research-use-only reference records the strings as nomenclature and explicitly declines to supply any dosing figure, administration route or schedule [13][14].

Do semaglutide and cagrilintide act on the same receptor?

No. Semaglutide is a GLP-1 receptor agonist, a class B G-protein-coupled receptor resolved by cryo-EM in 2017 [5], while cagrilintide acts at the calcitonin/amylin receptor family assembled from the calcitonin receptor plus a RAMP subunit [8]. They belong to different receptor systems and are grouped here for nomenclature only.

Works Cited

1. Lau J, Bloch P, Schäffer L, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370-7380. PMID: 26308095. doi:10.1021/acs.jmedchem.5b00726
2. Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. PMID: 31031702. doi:10.3389/fendo.2019.00155
3. Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018;27(4):740-756. PMID: 29617641. doi:10.1016/j.cmet.2018.03.001
4. Deacon CF, Johnsen AH, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126-1131. PMID: 7657039. doi:10.2337/diab.44.9.1126
5. Zhang Y, Sun B, Feng D, et al. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein. Nature. 2017;546(7657):248-253. PMID: 28538729. doi:10.1038/nature22394
6. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. PMID: 32213703. doi:10.1172/jci.insight.133429
7. Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64(15):11183-11194. PMID: 34288673. doi:10.1021/acs.jmedchem.1c00565
8. Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67(3):564-600. PMID: 26071095. doi:10.1124/pr.115.010629
9. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736-1748. PMID: 33894838. doi:10.1016/S0140-6736(21)00845-X
10. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-454. PMID: 25738459. doi:10.1016/j.cmet.2015.02.009
11. Kim SJ, Xiao J, Wan J, Cohen P, Yen K. Mitochondrially derived peptides as novel regulators of metabolism. J Physiol. 2017;595(21):6613-6621. PMID: 28574175. doi:10.1113/JP274472
12. Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat. Neuropsychopharmacology. 2010;35(7):1464-1476. PMID: 20200509. doi:10.1038/npp.2010.16
13. Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913. PMID: 18950853. doi:10.1016/S0140-6736(08)61525-1
14. Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. Nutr Rev. 2009;67(11):615-623. PMID: 19906248. doi:10.1111/j.1753-4887.2009.00246.x
15. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544-575. PMID: 20143256. doi:10.1007/s11095-009-0045-6